Generation of Allo-Compatible T Cells Through Engineered Protein Competition

Time: 10:00 am

Details:

• Selective replacement of αβTCR surface expression reduces the requirement for
  gene editing of allogeneic cell therapies
• Highly potent tumor targeting by αβT cells expressing specific γδTCRs (TEG)
• Broadly applicable strategy for building allogeneic T cell platforms that retain
  native recognition and signaling properties
• Compatibility with both DNA- and RNA-level editing